Citations

Showing 10 of 108162 citations.

Sex‐based limits to running speed in the human, horse and dog: The role of sexual dimorphisms
Senefeld, Jonathon W. , Shepherd, John R.A. , Baker, Sarah E. , Joyner, Michael J. , Joyner, Michael J , Senefeld, Jonathon W , Baker, Sarah E

Mayo Clinic

The FASEB Journal | April 29, 2021 | Volume: 35 | Issue: 5 | Pages: No page available

10.1096/fj.202100161r | PMID 33913189 Get It

Abstract Elite performing men continue to record faster record times in running events compared to women. These sex‐based differences in running speed and endurance in humans are expected based on sexual dimorphisms that contribute to differences in the determinants of aerobic performance. Comparatively, the sexual dimorphisms contributing to sex‐based differences in elite aerobic performance are not ubiquitous across other species that compete in running events. The purpose of this review is to offer a framework and model for ongoing discussions of the physiological determinants and ultimately limits of physical performance. The records for average running speed of champion athletes were delineated by sex for thoroughbred horses, greyhound dogs, and humans. Male and female performances within each of these species are being optimized by training, nutrition, and financial incentives, and are approaching a performance maximum. For horses and greyhounds breeding also plays a role. Analysis of athletic records shows that there is a sex‐related difference of ~10% or more in elite athletic performance for humans; however, the upper limit of performance does not appear to be different between sexes for thoroughbred horses and greyhound dogs. In the context of the nil sex differences in running performance in thoroughbreds and greyhounds, we discuss the physiological role of sexual dimorphisms on sex‐specific limits to running performance. We highlight that studies on both human and animal performance in athletic events stimulate critical physiological questions and drive novel research.
Photophobia and allodynia in persistent post-traumatic headache are associated with higher disease burden
Millsap, Leah, Rea, Natalie, Sciarretta, Christopher, Brennan, K. C. , Rea, Natalie A, Brennan, K C , Cortez, Melissa

Mayo Clinic

Cephalalgia | April 29, 2021 | Volume: 41 | Issue: 10 | Pages: 1089-1099

10.1177/03331024211010304 | PMID 33910382 Get It

Objective To assess photophobia and allodynia in subjects with post-traumatic headache and examine how these sensory hypersensitivities associate with clinical measures of disease burden. Background Post-traumatic headache is the most frequent and disabling long-term consequence of mild traumatic brain injury. There is evidence of sensory dysfunction in acute post-traumatic headache, and it is known from other headache conditions that sensory amplifications correlate with more severe disease. However, systematic studies in post-traumatic headache are surprisingly scarce. Methods We tested light and tactile sensitivity, along with measures of disease burden, in 30 persistent post-traumatic headache subjects and 35 controls. Results In all, 79% of post-traumatic headache subjects exhibited sensory hypersensitivity based on psychophysical assessment. Of those exhibiting hypersensitivity, 54% exhibited both light and tactile sensitivity. Finally, sensory thresholds were correlated across modalities, as well as with headache attack frequency. Conclusions In this study, post-traumatic headache subjects with both light and tactile sensitivity had significantly higher headache frequencies and lower sensitivity thresholds to both modalities, compared to those with single or no sensory hypersensitivity. This pattern suggests that hypersensitivity across multiple modalities may be functionally synergistic, reflect a higher disease burden, and may serve as candidate markers of disease.
Contrast-enhanced Mammography: A Guide to Setting Up a New Clinical Program
Kim, Geunwon , Patel, Bhavika , Du, Linda, Mehta, Rashmi , Phillips, Jordana , Patel, Bhavika K , Mehta, Tejas S.

Mayo Clinic

Journal of Breast Imaging | April 28, 2021 | Volume: 3 | Issue: 3 | Pages: 369-376

10.1093/jbi/wbab027 | PMID 38424777 Get It

Abstract Contrast-enhanced mammography (CEM) is gaining rapid traction following the U.S. Food and Drug Administration approval for diagnostic indications. Contrast-enhanced mammography is an alternative form of mammography that uses a dual-energy technique for image acquisition after the intravenous administration of iodinated contrast material. The resulting exam includes a dual set of images, one that appears similar to a routine 2D mammogram and one that highlights areas of contrast uptake. Studies have shown improved sensitivity compared to mammography and similar performance to contrast-enhanced breast MRI. As radiology groups incorporate CEM into clinical practice they must first select the indications for which CEM will be used. Many practices initially use CEM as an MRI alternative or in cases recommended for biopsy. Practices should then define the CEM clinical workflow and patient selection to include ordering, scheduling, contrast safety screening, and managing imaging on the day of the exam. The main equipment requirements for performing CEM include CEM-capable mammography equipment, a power injector for contrast administration, and imaging-viewing capability. The main staffing requirements include personnel to place the intravenous line, perform the CEM exam, and interpret the CEM. To safely and appropriately perform CEM, staff must be trained in their respective roles and to manage potential contrast-related events. Lastly, informing referring colleagues and patients of CEM through marketing campaigns is helpful for successful implementation.
Rapid Antimicrobial Susceptibility Testing on Clinical Urine Samples by Video-Based Object Scattering Intensity Detection
Zhang, Fenni , Jiang, Jiapei, McBride, Michelle, Yang, Yunze , Mo, Manni , Peterman, Joseph, Tao, Nongjian , Mo, Manni , Grys, Thomas, Wang, Shaopeng , Zhang, Fenni , Zhou, Xinyu , Grys, Thomas E. , Haydel, Shelley E. , Wang, Shaopeng

Mayo Clinic

Analytical Chemistry | April 28, 2021 | Volume: 93 | Issue: 18 | Pages: 7011-7021

10.1021/acs.analchem.1c00019 | PMID 33909404 Get It

Assessment of fixed‐duration therapies for treatment‐naïve Waldenström macroglobulinemia
Abeykoon, Jithma P. , Zanwar, Saurabh , Ansell, Stephen M. , Muchtar, Eli , He, Rong , Greipp, Patricia T. , King, Rebecca L. , Ailawadhi, Sikander , Larsen, Jeremy T. , Inwards, David J. , Thanarajasingam, Gita , Thompson, Carrie A. , Lacy, Martha Q. , Nowakowski, Grzegorz S. , Dingli, David , Kyle, Robert A. , Sher, Taimur , Chanan‐Khan, Asher , Reeder, Craig B. , Kumar, Shaji , Kapoor, Prashant , Paludo, Jonas , Inwards, David J , Dispenzieri, Angela , Witzig, T.E. , Lacy, Martha, Gonsalves, Wilson , Rajkumar, S Vincent , Rosenthal, Allison , Chanan-Khan, Asher A., Reeder, Craig, Gertz, Morie A , Kumar, Shaji K , Kapoor, Prashant , Muchtar, E , Ailawadhi, Sikander , Dingli, David , Greipp, Patricia T , Paludo, Jonas , Habermann, Thomas M. , Go, Ronald S. , Buadi, Francis K. , Dispenzieri, Angela , Witzig, Thomas E. , Gonsalves, Wilson I. , Rajkumar, S. Vincent , Roy, Vivek , Gertz, Morie A.

Mayo Clinic

American Journal of Hematology | April 28, 2021 | Volume: 96 | Issue: 8 | Pages: 945-953

10.1002/ajh.26210 | PMID 33909933 Get It

Abstract Comparative data guiding initial therapy for Waldenström macroglobulinemia (WM), an infrequently encountered non‐Hodgkin lymphoma, are sparse. We evaluated three commonly used rituximab‐based frontline regimens: rituximab‐bendamustine (R‐Benda); dexamethasone, rituximab, cyclophosphamide (DRC); and bortezomib, dexamethasone, rituximab (BDR) in 220 treatment‐naïve patients with WM, seen at Mayo Clinic between November 1, 2000 and October 31, 2019. The median follow‐up was 4.5 (95%CI: 4–5) years. The R‐Benda cohort (n = 83) demonstrated superior overall response rate (ORR: 98%), in comparison to DRC (n = 92, ORR: 78%) or BDR (n = 45, ORR: 84%) cohorts, p = 0.003. Similarly, longer progression‐free survival (PFS) was evident with R‐Benda use [median 5.2 vs. 4.3 (DRC) and 1.8 years (BDR), p < 0.001]. The time‐to‐next therapy (TTNT) favored R‐Benda [median, not‐reached, 4.4 (DRC) and 2.6 years (BDR), p < 0.001). These endpoints were comparable between the DRC and BDR cohorts. Overall survival (OS) was similar across the three cohorts, p = 0.77. In a subset analysis of 142 patients genotyped for MYD88 L265P mutation, the ORR, PFS and TTNT were unaffected by the patients' MYD88 signature within each cohort. In conclusion, ORR, PFS and TTNT with R‐Benda are superior compared to DRC or BDR in treatment‐naïve patients with active WM. The patient outcomes with any one of these three regimens are unaffected by the MYD88 L265P mutation status.
Feasibility of Cell-Free DNA Collection and Clonal Immunoglobulin Sequencing in South African Patients With HIV-Associated Lymphoma
Vogt, Samantha L. , Patel, Moosa , Lakha, Atul , Philip, Vinitha , Omar, Tanvier , Ashmore, Philippa , Pather, Sugeshnee , Haley, Lisa , Zheng, Gang , Mayne, Elizabeth , Stevens, Wendy , Wagner‐Johnston, Nina D. , Gocke, Christopher D. , Martinson, Neil , Ambinder, Richard F. , Xian, Rena R. , Gocke, Christopher D , Ambinder, Richard F , Stone, Jennifer

Mayo Clinic

JCO Global Oncology | April 28, 2021 | Volume: No volume available | Issue: 7 | Pages: 611-621

10.1200/go.20.00651 | PMID 33909482 Get It

PURPOSEDiagnosis of AIDS lymphoma in low-resource settings, like South Africa, is often delayed, leaving patients with limited treatment options. In tuberculosis (TB) endemic regions, overlapping signs and symptoms often lead to diagnostic delays. Assessment of plasma cell-free DNA (cfDNA) by next-generation sequencing (NGS) may expedite the diagnosis of lymphoma but requires high-quality cfDNA.METHODSPeople living with HIV with newly diagnosed aggressive B-cell lymphoma and those with newly diagnosed TB seeking care at Chris Hani Baragwanath Academic Hospital and its surrounding clinics, in Soweto, South Africa, were enrolled in this study. Each participant provided a whole blood specimen collected in cell-stabilizing tubes. Quantity and quality of plasma cfDNA were assessed. NGS of the immunoglobulin heavy chain was performed.RESULTSNine HIV+ patients with untreated lymphoma and eight HIV+ patients with TB, but without lymphoma, were enrolled. All cfDNA quantity and quality metrics were similar between the two groups, except that cfDNA accounted for a larger fraction of recovered plasma DNA in patients with lymphoma. The concentration of cfDNA in plasma also trended higher in patients with lymphoma. NGS of immunoglobulin heavy chain showed robust amplification of DNA, with large amplicons (> 250 bp) being more readily detected in patients with lymphoma. Clonal sequences were detected in five of nine patients with lymphoma, and none of the patients with TB.CONCLUSIONThis proof-of-principle study demonstrates that whole blood collected for cfDNA in a low-resource setting is suitable for sophisticated sequencing analyses, including clonal immunoglobulin NGS. The detection of clonal sequences in more than half of patients with lymphoma shows promise as a diagnostic marker that may be explored in future studies.
Functional megalin is expressed in renal cysts in a mouse model of adult polycystic kidney disease
Nielsen, Marlene Louise , Mundt, Mia C, Lildballe, Dorte L. , Rasmussen, Maria , Sunde, Lone , Torres, Vicente E. , Harris, Peter C. , Nielsen, Marlene L , Harris, Peter C , Torres, Vicente E , Sunde, Lone , Birn, Henrik

Mayo Clinic

Clinical Kidney Journal | April 28, 2021 | Volume: 14 | Issue: 11 | Pages: 2420-2427

10.1093/ckj/sfab088 | PMID 34754438 Get It

Abstract Background Autosomal dominant polycystic kidney disease (ADPKD) is characterized by the progressive growth of cysts and a decline of renal function. The clinical feasibility of the number of potential disease-modifying drugs is limited by systemic adverse effects. We hypothesize that megalin, a multiligand endocytic receptor expressed in the proximal tubule, may be used to facilitate drug uptake into cysts, thereby allowing for greater efficacy and fewer side effects. Methods The cyst expression of various tubular markers, including megalin and aquaporin 2 (AQP2), was analysed by immunohistochemistry (IHC) of kidney sections from the ADPKD mouse model (PKD1RC/RC) at different post-natal ages. The endocytic function of megalin in cysts was examined by IHC of kidney tissue from mice injected with the megalin ligand aprotinin. Results Cyst lining epithelial cells expressing megalin were observed at all ages; however, the proportion decreased with age. Concomitantly, an increasing proportion of cysts revealed expression of AQP2, partial expression of megalin and/or AQP2 or no expression of the examined markers. Endocytic uptake of aprotinin was evident in megalin-positive cysts, but only in those that remained connected to the renal tubular system. Conclusions Megalin-expressing cysts were observed at all ages, but the proportion decreased with age, possibly due to a switch in tubular origin, a merging of cysts of different tubular origin and/or a change in the expression pattern of cyst lining cells. Megalin expressed in cysts was functional, suggesting that megalin-mediated endocytosis is a potential mechanism for drug targeting in ADPKD if initiated early in the disease.
Diagnostic Accuracy of MRI for the Detection of Malignant Peripheral Nerve Sheath Tumors: A Systematic Review and Meta-Analysis
Wilson, Mitchell P. , Katlariwala, Prayash , Low, Gavin , Jacques, Line , Jack, Andrew , Murad, Mohammad H, Murad, M. Hassan , McInnes, Matthew D. F.

Mayo Clinic

American Journal of Roentgenology | April 28, 2021 | Volume: 217 | Issue: 1 | Pages: 31-39

10.2214/ajr.20.23403 | PMID 33909462 Get It

Racial and ethnic disparities in coronary, vascular, structural, and congenital heart disease
Grines, Cindy L. , Klein, Andrew , Bauser‐Heaton, Holly , Aggarwal, Varun , Altin, S. Elissa , Batchelor, Wayne , Blankenship, James C. , Fakorede, Foluso , Hawkins, Beau, Hernandez, Gabriel A. , Ijioma, Nkechinyere , Keeshan, Britton , Pineda, Andrés M. , Sandoval, Yader , Young, Michael N. , Aggarwal, Varun , Altin, S Elissa , Batchelor, Wayne B , Blankenship, James C , Ligon, R Allen , Pineda, Andres , Grines, Cindy L , Ijioma, Nkechi , Alkhouli, Mohamad , Katukuri, Neelima , Hawkins, Beau M., Li, Jun

Mayo Clinic

Catheterization and Cardiovascular Interventions | April 28, 2021 | Volume: 98 | Issue: 2 | Pages: 277-294

10.1002/ccd.29745 | PMID 33909339 Get It

AbstractCardiovascular disease (CVD) remains the leading cause of death in the United States. However, percutaneous interventional cardiovascular therapies are often underutilized in Blacks, Hispanics, and women and may contribute to excess morbidity and mortality in these vulnerable populations. The Society for Cardiovascular Angiography and Interventions (SCAI) is committed to reducing racial, ethnic, and sex‐based treatment disparities in interventional cardiology patients. Accordingly, each of the SCAI Clinical Interest Councils (coronary, peripheral, structural, and congenital heart disease [CHD]) participated in the development of this whitepaper addressing disparities in diagnosis, treatment, and outcomes in underserved populations. The councils were charged with summarizing the available data on prevalence, treatment, and outcomes and elucidating potential reasons for any disparities. Given the huge changes in racial and ethnic composition by age in the United States (Figure 1), it was difficult to determine disparities in rates of diagnosis and we expected to find some racial differences in prevalence of disease. For example, since the average age of patients undergoing transcatheter aortic valve replacement (TAVR) is 80 years, one may expect 80% of TAVR patients to be non‐Hispanic White. Conversely, only 50% of congenital heart interventions would be expected to be performed in non‐Hispanic Whites. Finally, we identified opportunities for SCAI to advance clinical care and equity for our patients, regardless of sex, ethnicity, or race.
Optimal pathological response after neoadjuvant chemotherapy for muscle‐invasive bladder cancer: results from a global, multicentre collaboration
Ravi, Praful , Pond, Gregory R. , Diamantopoulos, Leonidas Nikolaos , Su, Christopher , Alva, Ajjai , Skelton, William Paul , Gupta, Sumati , Olson, Kathleen M., Grunewald, Camilla M. , Mossanen, Matthew , Curran, Catherine , Grivas, Petros , Sonpavde, Guru , Singh, Parminder , Skelton, William P , Bandini, Marco , Necchi, Andrea , Mossanen, Matthew , Su, Christopher , Pond, Gregory Russell , Diamantopoulos, Leonidas N , Singh, Parminder , Jain, Rohit , Tward, Jonathan D. , Singh, Parminder Pal , Niegisch, Günter , Lee, Jae‐Lyun , Gallina, Andrea , Necchi, Andrea , McGregor, Bradley A.

Mayo Clinic

BJU International | April 28, 2021 | Volume: 128 | Issue: 5 | Pages: 607-614

10.1111/bju.15434 | PMID 33909949 Get It

Objectives To evaluate outcomes of patients achieving a post‐treatment pathological stage of <ypT2N0 at radical cystectomy (RC) following neoadjuvant chemotherapy (NAC) for muscle‐invasive bladder cancer (MIBC) to identify an optimal definition of pathological response. Patients and Methods Patients from 10 international centres who underwent NAC for cT2–4aN0–1 MIBC and achieved <ypT2N0 disease at RC were included. The primary outcome was time to recurrence, either local or distant. Kaplan–Meier and Cox proportional hazards regression were used to evaluate associations between clinicopathological variables and outcomes. Results A total of 625 patients were included. The median age was 66 years and 80% were male. Gemcitabine and cisplatin (GC, 56%) and methotrexate, vinblastine, doxorubicin and cisplatin (MVAC)/dose‐dense (dd)MVAC (32%) were the most common NAC regimens. ypT0, pure ypTis, ypTa ±ypTis and ypT1 ± ypTis were attained in 58.1%, 20.0%, 7.6% and 14.2% of patients, respectively. The cumulative incidence of recurrence at 5 years was 9%, 16%, 29% and 30%, respectively. Pathological stage was prognostic for recurrence, with ypTa ± Tis (hazard ratio [HR] 3.20, 95% confidence interval [CI] 1.40–7.30) and ypT1 ± Tis disease (HR 4.03, 95% CI 2.13–7.63) associated with a significantly higher recurrence risk. Pure ypTis (HR 1.66, 95% CI 0.82–3.38) and the type of NAC regimen (ddMVAC: HR 1.59, 95% CI 0.55–4.56; MVAC: HR 1.18, 9%% CI 0.25–5.54; reference: GC) were not associated with recurrence. Conclusion We propose that optimal pathological response after NAC be defined as attainment of ypT0N0/ypTisN0 at RC. Patients with ypTaN0 or ypT1N0 disease (with or without Tis) at RC displayed a significantly higher risk of recurrence and may be candidates for trials investigating adjuvant therapy.